Paul R. Kimmel Named MediCor Chief Financial Officer, Replaces Tom Moyes
17 March 2006 - 12:44PM
PR Newswire (US)
LAS VEGAS, March 16 /PRNewswire-FirstCall/ -- Las Vegas-based
MediCor Ltd. (OTC:MDCR) (BULLETIN BOARD: MDCR) , the world's third
largest manufacturer and distributor of breast implants, today
announced Paul R. Kimmel has been named the Company's Chief
Financial Officer, replacing Tom Moyes, who concurrently resigned
from that position. Mr. Kimmel served with MediCor's competitor and
the world's largest breast implant manufacturer, Inamed Corporation
from 2000 to November 2005, at which point he joined MediCor as
Executive Vice President and Financial Controller. He has
significant industry experience and expertise in the areas of
business and financial accounting, external audit management,
Securities and Exchange Commission reporting and financial planning
and analysis. In addition to speaking Spanish, French and German,
Mr. Kimmel is a member of the American Institute of Certified
Public Accountants, the Nevada Society of Certified Public
Accountants, Financial Executives International and the Institute
of Management Accountants. Mr. Kimmel is 58 years old and a
Certified Public Accountant. He holds a B.S. in Engineering from
the Case Institute of Technology an M.B.A. from the Harvard
Business School. About MediCor Ltd. MediCor was founded by Chairman
of the Board Donald K. McGhan, the pioneer of the modern day breast
implant industry. The Company acquires, develops, manufactures and
markets products for medical specialties in aesthetic, plastic and
reconstructive surgery and dermatology markets. Products include
surgically implantable prostheses for aesthetic, plastic and
reconstructive surgery and scar management products. Its products
are sold worldwide to hospitals, surgery centers and physicians
through various distributors and direct sales personnel. MediCor's
strategy is to be the leading integrator of selected international
medical device markets, technologies and corporations. To achieve
this strategy, MediCor intends to build upon and expand its
business lines, primarily in the aesthetic, plastic and
reconstructive surgery and dermatology markets. MediCor intends to
accomplish this growth through the expansion of existing product
lines and offerings and through the acquisition of companies and
other assets, including intellectual property rights or
distribution rights. Additional information about MediCor can be
found on MediCor's website (http://www.medicorltd.com/) and in
MediCor's Annual Report on Form 10-KSB for the year ended June 30,
2005, which was filed with the Securities and Exchange Commission
and is available at the Securities and Exchange Commission's
website (http://www.sec.gov/). DATASOURCE: MediCor Ltd. CONTACT:
Marc S. Sperberg of MediCor Ltd., +1-702-932-4560, ext. 308; or
Mark Collinson of CCG Investor Relations, +1-310-231-8600, ext.
117, for MediCor Ltd. Web site: http://www.medicorltd.com/
Copyright